RhumbLine Advisers’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

RhumbLine Advisers’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-37,155	Closed	-$150K	–	4293
2023 Q4	$150K	Buy	37,155 +9,197	+33%	+$28.1K	﹤0.01%	3310
2023 Q3	$75.2K	Buy	27,958 +661	+2%	+$2.59K	﹤0.01%	3547
2023 Q2	$255K	Buy	27,297 +1,475	+6%	+$14.5K	﹤0.01%	3107
2023 Q1	$229K	Buy	25,822 +820	+3%	+$8.05K	﹤0.01%	2705
2022 Q4	$125K	Buy	25,002 +154	+0.6%	+$902	﹤0.01%	2877
2022 Q3	$144K	Buy	24,848 +1,443	+6%	+$10.2K	﹤0.01%	2956
2022 Q2	$129K	Buy	+23,405	New	+$193K	﹤0.01%	3010

RhumbLine Advisers's THRX Position: Q1 2024 in Review

RhumbLine Advisers sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 37,155 shares — an estimated $150K sold.

RhumbLine Advisers first reported a position in THRX in Q2 2022 and held it in 7 quarters. The position peaked at $255K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

RhumbLine Advisers reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
RhumbLine Advisers sold 37,155 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $150K.
RhumbLine Advisers first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
RhumbLine Advisers's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $255K in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on RhumbLine Advisers's 13F filing for Q1 2024, filed 9 May 2024.